Funding for this research was provided by:
Cystic Fibrosis Canada
Gilead Sciences
Michael Smith Foundation for Health Research
Article History
Received: 15 April 2020
Accepted: 21 August 2020
First Online: 31 August 2020
Ethics approval and consent to participate
: Not applicable.
: Informed and signed consent was provided by the patient for this publication.
: G. Y. L., P. W. and J. G. report no conflicts of interest. B. S. Q reports personal fees from Vertex Pharmaceuticals and personal fees from Proteostasis Therapeutics, and grants from CF Canada, CF Foundation, Gilead Sciences and BC Lung Association.